18889881171
Kalkine 0
countryflagUS
L

AAPL 198.3455 4.1621% MSFT 389.1451 2.0441% NVDA 110.43 2.6587% GOOGL 156.66 2.5128% GOOG 159.005 2.3396% AMZN 184.0298 1.5505% META 541.29 -0.9153% AVGO 180.46 4.7359% LLY 728.565 1.0619% TSLA 248.7306 -1.4538% TSM 157.44 4.1752% V 334.18 2.9482% JPM 237.7 4.6629% UNH 601.395 1.1768% NVO 64.53 5.424% WMT 92.6206 2.219% LVMUY 120.59 2.143% XOM 103.37 3.4424% LVMHF 608.15 3.0763% MA 511.0484 2.3448%
AAPL 198.3455 4.1621% MSFT 389.1451 2.0441% NVDA 110.43 2.6587% GOOGL 156.66 2.5128% GOOG 159.005 2.3396% AMZN 184.0298 1.5505% META 541.29 -0.9153% AVGO 180.46 4.7359% LLY 728.565 1.0619% TSLA 248.7306 -1.4538% TSM 157.44 4.1752% V 334.18 2.9482% JPM 237.7 4.6629% UNH 601.395 1.1768% NVO 64.53 5.424% WMT 92.6206 2.219% LVMUY 120.59 2.143% XOM 103.37 3.4424% LVMHF 608.15 3.0763% MA 511.0484 2.3448%

mid-cap

Watch Out for One NASDAQ- Listed Biotechnology Stock– TransCode Therapeutics Inc

Jan 29, 2025 | Team Kalkine
Watch Out for One NASDAQ- Listed Biotechnology Stock– TransCode Therapeutics Inc
Image source: shutterstock

RNAZ:NASDAQ
Investment Type
Mid - Cap
Risk Level
Action
Rec. Price (US$)

TransCode Therapeutics Inc

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) is a clinical-stage oncology company focused on treating metastatic disease. The Company is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis.

Recent Business and Financial Updates

Xxxxxx Xxxxxx Xxxxxx

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx

  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx
  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .   

Interested?

Enter your details below and our team will help you to decide if this product is best for you.
  • Australia+61
  • Canada+1
  • India (भारत)+91
  • New Zealand+64
  • United Kingdom+44
  • United States+1
By submitting my details and clicking on the button below, I agree to Kalkine’s Terms and Conditions and Privacy Policy.
I agree to receive marketing calls from Kalkine on the phone number I have provided above. I understand and agree that these calls may be placed using an auto-dialer and that my consent is not a condition of any purchase.
Please wait processing your request...
Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Mid-Cap
An Update on One NYSE- Listed Media & Entertainment Stock - NMAX
Apr 11, 2025 Team Kalkine
Small-Cap
One NASDAQ- Listed Information Technology Stock Under Radar - ARBE
Apr 11, 2025 Team Kalkine
Blue-Chip
One NYSE-Listed Mining Stock at Resistance Levels – Newmont Corporation
Apr 11, 2025 Team Kalkine
Blue-Chip
Technical Weakness in this NYSE- Listed Financial Stock: NU
Apr 11, 2025 Team Kalkine
Small-Cap
Update in this NASDAQ- Listed Advertising Stock: GAMB
Apr 11, 2025 Team Kalkine